Scientific Publications (Google Scholar H Factor 77; Pubmed bibliography)

242. Maeusli M, Skandalis N, Lee B, Lu P, Miller S, Yan J, Talyansky Y, Li R, Reyna Z, Guerrero N, Ulhaq A, Slarve M, Theologidis I, Spellberg B, Luna B.  Acacia Fiber Protects the Gut from Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Colonization Enabled by Antibiotics.  mSphere.  2022.  ePub.

241. Spellberg B, Aggrey G, Brennan MB, Footer B, Forrest G, Hamilton F, Minejima E, Moore J, Ahn J, Angarone M, Centor RM, Cherabuddi K, Curran J, Davar K, Davis J, Qin Dong M, Ghanem B, Hutcheon D, Jent P, Kang M, Lee R, McDonald E, Morris AM, Reece R, Schwartz IS, So M, Tong S, Tucker C, Wald-Dickler N, Weinstein EJ, Williams II R, Yen C, Zhou 0S, Lee TC, on behalf of WikiGuidelines.  Management of Pyogenic Osteomyelitis in Adults: A WikiGuidelines Consensus Statement.  JAMA Network Open.  2022.  5(5):e2211321.

240. Spellberg B, Rice LB.  The Shorter Is Better movement: past, present, future.  Clin Microbiol Infect.  2022.  ePub.

239. Chambers TN, Opas L, Spellberg B.  A Collaborative Approach to Safety, Equity, and Fairness by Medical Staff, Graduate Medical Education, Human Resources, and Law Enforcement.  J Grad Med Educ.  2021.  13:768-70.

238. Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, Kan C, Phillips MC, Cho E, Canamar C, Holtom P, Spellberg B.  Fosfomycin versus Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort

Study.  Open Forum Infect Dis.  9(1):ofab620. doi: 10.1093/ofid/ofab620. 

237. Gaffin N, Spellberg B.  Sustained reductions in unnecessary antimicrobial administration and hospital Clostridioides difficile rates via stewardship in a nonacademic setting.  2021.  Infect Control Hospital Epidemiol.  ePub.

236. Centor RM, Spellberg B, Shaneyfelt T.  Annals on Call—Guidelines with Humility.  2021.  Ann Int Medicine.  174(12):OC1. doi: 10.7326/A20-0026.

235. Lee B, Yan J, Ulhaq A, Miller S, Seo W, Lu P, She R, Spellberg B, Luna B.  In Vitro and In Vivo Activity of Rifabutin and Rifampin against Antibiotic-Resistant A. baumannii, E. coli, S. aureus, P. aeruginosa, and K. pneumoniae.  2021.  mSphere.  ePub.

234. Wald-Dickler N, Holtom PD, Phillips MC, Centor RM, Lee RA, Baden R, Spellberg B.  Oral Is the New IV--Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review. 2021.  Am J Med.  S0002-9343(21)00699-9.

233. Spellberg B, Shorr AF.  Opinion-Based Recommendations: Beware the Tyranny of Experts.  2021.  Open Forum Infect Dis.  8(11):ofab490.

232. Spellberg B, Wright WF, Shaneyfelt T, Centor RM.  The Future of Medical Guidelines—Standardizing Clinical Care with the Humility of Uncertainty.  Ann Int Med.  2021.  174(12):1740-1742.

231. Masood M, Panek D, Butler-Wu S, Spellberg B.  A pain in the flank.  Infect Dis Clinical Practice.  2021.  In Press.**

230. Phillips MC, Sarff L, Banerjee J, Coffey C, Holtom P, Meurer S, Wald-Dickler N, Spellberg B.  Effect of Mortality from COVID-19 on Inpatient Outcomes.  J Medical Virol.  2021.  94(1):318-326.

229. Hinchliffe P, Moreno DM, Rossi MA, Mojica MF, Martinez V, Villamil V, Spellberg B, Drusano GL, Banchio C, Mahler G, Bonomo RA, Vila AJ, Spencer J.  2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-β-Lactamase Classes by Maintaining a Conserved Binding Mode.  ACS Infect Dis.  2021.  7:2697-2706.

228. Nielsen TB, Yan J, Slarve M, Lu P, Li R, Ruiz J, Lee B, Burk E, Talyansky Y, Oelschlaeger P, Hurth K, Win W, Luna BM, Bonomo RA, Spellberg B.  Monoclonal Antibody Therapy against Acinetobacter baumannii.  Infection Immun.  2021.  89(10):e0016221.

227. Rossi MA, Martinez V, Hinchliffe P, Mojica MF, Castillo V, Moreno DM, Smith R, Spellberg B, Drusano GL, Banchio C, Bonomo RA, Spencer J, Vila AJ, Mahler G.  2-Mercaptomethyl-thiazolidines use conserved aromatic-S interactions to achieve broad-range inhibition of metallo-β-lactamases.  Chem Sci.  2021.  12:2898-2908.

226. Feldman BJ, Kim JS, Mosqueda L, Vongsachang H, Banerjee J, Coffey CE Jr, Spellberg B, Hochman M, Robinson J.  From the hospital to the streets: Bringing care to the unsheltered homeless in Los Angeles.  2021.  Healthc (Amst).  9:00557.

225. Nielsen TB, Yan J, Luna BM, Talyansky Y, Slarve M, Bonomo RA, Spellberg B.  Monoclonal antibody requires immunomodulation for efficacy against Acinetobacter baumannii infection.  J Infect Dis.  2021.  224(12):2133-2147.

224. Centor RM, Lee RA, Spellberg B.  Web Exclusive. Annals On Call - The Right Antibiotic, for the Right Infection, and for the Right Duration.  Ann Int Med.  2021.  174(5):OC1.

223. Sargent RE, Sener SF, Amaya R, Vazquez E, Bowdish ME, Spellberg B.  SARS-CoV-2-related outcomes after surgical procedures on SARS-CoV-2-positive patients in a large, urban, safety net medical center.  Surg Open Sci.  2021.  5:10-13.

222. Banerjee J, Canamar CP, Voyageur C, Tangpraphaphorn S, Lemus A, Coffey Jr C, Wald-Dickler N, Holtom P, Shoenberger J, Bowdish M, Yee HF, Spellberg B.  Mortality and Readmission Rates Among Patients With COVID-19 After Discharge From Acute Care Setting With Supplemental Oxygen.  JAMA Open Network.  2021. 4(4):e213990.

221. Jorgensen S, Spellberg B, Shorr AF, Wright WF.  Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections? - No.  Clin Infect Dis. 72:1502-1506.

220. Minejima E, Wang J, Boettcher S, Liu L, Lou M, She RC, Wenzel SL, Spellberg B, Wong-Beringer A.  Distance Between Home and the Admitting Hospital and Its Effect on Survival of Low Socioeconomic Status Population With Staphylococcus aureus Bacteremia.  Public Health Rep.  2021.  137(1):110-119.

219. ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas CE, et al.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.  New Eng J Med.  2021.  384(10):905-914.

218. Talyansky Y, Nielsen TB, Yan J, Carlino-Macdonald U, Di Venanzio G, Chakravorty S, Ulhaq A, Feldman MF, Russo TA, Vinogradov E, Luna B, Wright MS, Adams MD, Spellberg B.  Capsule carbohydrate structure determines virulence in Acinetobacter baumannii.  PLoS Pathogens.  2021.  7:e1009291.  PMCID: PMC7880449.

217. Cheng J, Yan J, Reyna Z, Slarve M, Lu P, Spellberg B, Luna B.  Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii.  Antimicrob Agents Chemother.  2021.  65:e02204-20.

216. Spellberg B, Nielsen TB, Casadevall A.  Antibodies, Immunity, and COVID-19.  JAMA Internal Medicine.  181(4):460-462.

215. Luu A, Dominguez F, Yeshoua B, Vo C, Nallapa S, Chung D, Wald-Dickler N, Butler-Wu SM, Khaleel H, Chang K, Canamar C, Holtom P, Spellberg B.  Reducing Catheter Associated Urinary Tract Infections via Cost-Saving Diagnostic Stewardship.  Clin Infect Dis.  72(11):e883-e886.

214. Phillips MC, Wald-Dickler N, Loomis K, Luna BM, Spellberg B.  2020.  Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Acinetobacter Infections.  Open Forum Infect Dis.  7(11):ofaa460.

213. Wright WF, Jorgenson SCJ, Spellberg B.  Heaping the Pelion of Vancomycin on the Ossa of MRSA: Back to Basics in Clinical Care and Guidelines.  2020.  Clin Infect Dis. 72(10):e682-e684.

212. Spellberg B.  Alignment with Market Forces: The “Re-Whithering” of Infectious Diseases.  2020.  Open Forum Infect Dis.  20;7(8):ofaa245.  PMCID: PMC7397831.

211. Luna B, Trebosc V, Lee B, Bakowski M, Ulhaq A, Yan J, Lu P, Cheng J, Nielsen T, Lim J, Ketphan W, Eoh H, McNamara C, Skandalis N, She R, Kemmer C, Lociuro S, Dale GE, Spellberg B.  A Novel Screen Unmasks Rifabutin Hyperactivity for XDR Acinetobacter baumannii.  Nature Microbiol.  5(9):1134-1143.  PMCID: PMC7483275.

210. Maeusli M, Lee B, Miller S, Reyna Z, Lu P, Yan J, Ulhaq A, Skandalis N, Spellberg B, Luna B. A. baylyi horizontal gene transfer to E. coli on lettuce and subsequent antibiotic resistance transmission to the gut microbiome.  2020.  mSphere.  5(3):e00329-20.  PMCID: PMCID: PMC7253597.

208. Spellberg B, Haddix M, Lee R, Butler-Wu S, Holtom P, Yee H, Gounder P.  Community Prevalence of SARS-CoV-2 Among Patients with Influenza-Like Illnesses Presenting to a Los Angeles Medical Center in March 2020.  2020.  JAMA.  323(19):1966-7.  PMCID: PMCID: PMC7110920.

208. Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS.  Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review.  2020  JAMA Int Med.  180(5):769-777.  PMCID: PMC7483894.

206. Shorr AF, Zilberberg M, Spellberg B, Kollef M.  Microbiologic Failure Despite Clinical Cure in Pneumonia: Cum Hoc and Post Hoc Ergo Propter Hoc.  2020.  Clin Infect Dis.  71(12):3042-3043.

205. Tolles J, Waterman G, Coffey CE Jr, Sandoval R, Fleischman RJ, Hess M, Sarff L, Lewis RJ, Spellberg B, on behalf of the BRAVE Study Group.  The Bed Rest Avoidance (BRAVE) Study.  PLoS One.  2020.  15(1):e0226332.

204. Spellberg B.  Are echinocandins superior in efficacy to azoles?  2020.  Clin Infect Dis.  70(9):2020-2021.

203. Wilson BM, Bessesen MT, Doros G, Brown ST, Saade E, Hermos J, Perez F, Skalweit M, Spellberg B, Bonomo RA.  Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration.  2019.  JAMA Network Open.  2(11):e1916003.  PMCID: PMCID: PMC6902814.

202. Spellberg B, Nielsen TB, Gilbert DN, Shorr AF, Brass EP.  Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.  2019.  Ann Int Med.  171:580-2.  PMCID: PMC7296826.

201. Luna BM, Yan J, Reyna Z, Moon E, Nielsen TB, Reza H, Bonomo R, Louie A, Drusano G, Bulitta J, She R, Spellberg B.  Natural history of Acinetobacter baumannii infection in mice.  2019.  PLoS One.  14(7):e0219824. PMCID: PMC6638954.

200. Nielsen TB, Brass EP, Gilbert DN, Bartlett JG, Spellberg B.  Sustainable Antibiotic Discovery and Development--Is a Nonprofit Approach the Future?  2019.  New Eng J Med.  381:503-505. PMCID: PMC6697094.

199. Chau E, Sarkarati M, Spellberg B.  Adenosine Deaminase diagnostic testing in Pericardial Fluid.  2019.  JAMA.  322:163-4. PMCID: PMC6697089.

198. Spellberg B, Rice LB.  Duration of Antibiotic Therapy: Shorter is Better.  2019.  Ann Int Med.  171:210-11.  PMCID PMC6736742.

197. Adaptive Platform Trials Coalition (Collaborators listed alphabetically, Angus D…Spellberg B…Woodcock J).  Adaptive Platform Trials: Definition, Design, Conduct, and Reporting Considerations.  2019.  Nature Rev Drug Discovery.  18:797-807.

196. Cornely OA…Spellberg B…Chakrabarti A (>50 authors total).  Global Guideline for the Diagnosis and Management of Mucormycosis: An initiative of the ECMM in cooperation with ESCMID/EFISG.  2019.  Lancet Infect Dis.  19:e405-e421.

195. Luna BM, Nielsen TB, Cheng B, Pantapalangkoor P, Yan J, Boyle-Vavra S, Bruhn KW, Montgomery C, Spellberg B, Daum R.  Vaccines Targeting Staphylococcus aureus Skin and Bloodstream Infections Require Different Composition.  2019.  PloS One.  14(6):e0217439.  PMCID: PMC6557488.

194. Luna BM, Ershova K, Yan J, Ulhaq A, Nielsen TB, Hsieh S, Pantapalangkoor P, Van Scoy B, Ambrose P, Rudin S, Hujer K, Bonomo RA, Actis L, Skaar EP, Spellberg B.  Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria.  2019.  J Antimicrob Chemother.  74:2631-9.  PMCID: PMC6736376.

193. Ambrose PG, VanScoy BD, Luna BM, Yan J, Ulhaq A, Nielsen TB, Rudin S, Hujer K, Bonomo RA, Actis L, Skaar E, Spellberg B.  Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect.  2019.  Antimicrobial Agents Chemother.  63:e00112-19.  PMCID: PMC6496049.

192. Minejima E, Mai N, Bui N, Mert M, She RC, Nieberg P, Spellberg B, Wong-Behringer A.  Defining breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes.  2020.  Clin Infect Dis.  70(4):566-573.

191. Wald-Dickler N, Spellberg B.  Short Course Antibiotic Therapy—Replacing Constantine Units with “Shorter Is Better”.  2019.  Clin Infect Dis.  69:1476-1479.  PMCID PMC6792080

190. Choi YJ, Kim S, Nielsen TB, Yan J, Lu A, Ruan J, Remold-O’Donnell E, Lee H-R, Wu H, Spellberg B, Jung JU.  SerpinB1-mediated checkpoint of inflammatory caspase activation.  2019.  Nat Immunol.  20:276-287.  PMCID: PMC6450391.

189. Wong D, Holtom P, Spellberg B.  Osteomyelitis complicating sacral pressure ulcers: whether or not to treat with antibiotic therapy.  2019.  Clin Infect Dis.  68:338-42. PMCID: PMC6594415.

188. Yadav K, Masuda E, Minejima E, Spellberg B.  Expected Practice as a Novel Antibiotic Stewardship Intervention.  2018.  Open Forum Infect Disease.  6:ofy319.  PMCID: PMC6324551.

187. Gaffin N, Spellberg B.  Procalcitonin Trial Does Not Reflect Clinical Practice.  2018.  New Eng J Medicine.  379:1972-3.

186. Nielsen TB, Yan J, Luna B, Spellberg B.  Murine Oropharyngeal Aspiration Model of Ventilator-Associated and Hospital-Acquired Bacterial Pneumonia.  2018.  JoVE.  28 (136). PMCID: PMC6102004.

185. Tchesnokova VL, Rechkina E, Larson L, Ferrier K, Weaver JL, Schroeder DW, She R, Butler-Wu SM, Aguero-Rosenfeld ME, Zerr D, Fang FC, Ralston J, Riddell K, Scholes D, Weissman S, Parker K, Spellberg B, Johnson JR, Sokurenko EV.  Rapid and Extensive Expansion in the U.S. of a New Multidrug-Resistant Escherichia coli Clonal Group, Sequence Type ST1193.  Clin Infect Dis.  2018.  68:334-7.

184. Coffey C, Cho E, Wei E, Luu A, Ho M, Amaya R, Pecson M, Dalton F, Kahaku D, Spellberg B, Sener S.  Lean methods to improve operating room elective first case on-time starts in a large, urban, safety net medical center.  2018.  Am J Surg.  216:194-201.

183. Yen C, Holtom P, Butler-Wu S, Wald-Dickler N, Shulman I, Spellberg B.  Reducing Clostridium difficile colitis rates via cost-saving diagnostic stewardship.  2018.  Infection Control Hospital Epidem.  39:734-6.

182. Spellberg B.  The Maturing Antibiotic Mantra: “Shorter Is Still Better”.  2018.  J Hosp Med.  13:361-2.

181. Coffey C Jr, Carter V, Wei E, Hutcheon D, Gruen JP, Anonas-Ternate A, Sandoval R, Marquez A, Sarff L, Spellberg B.  No More “Code Black”: Intervention to Improve Inpatient Flow at a Large Public Hospital.  2018.  Am J Med.  131:371-376.

180. Wald-Dickler N, Holtom P, Spellberg B.  Busting the Myth of “Static vs. Cidal”: A Systematic Literature Review.  2017.  Clin Infect Dis.  66:1470-4.  PMCID: PMC5905615.

179. Barnes MD, Winkler ML, Taracila MA, Page MGP, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA.  Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic resistant phenotypes emerge from β-lactamase protein engineering.  2017.  mBio.  e00528-17.

178. Spellberg B.  Mucormycosis pathogenesis: Beyond Rhizopus.  2017.  Virulence.  8:1481-2.  PMCID: PMC5810489.

177. Nielsen TB, Pantapalangkoor P, Yan J, Luna BM, Dekitani K, Bruhn KW, Tan B, Junus J, Bonomo RA, Schmidt AM, Everson M, Duncanson F, Doherty TM, Lin L, Spellberg B.  Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE.  2017.  mBio.  8:e00818-17.  PMCID: PMC5565964.

176. Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, Yan J, Dekitani K, Hsieh S, Yeshoua B, Pascual B, Vinogradov E, Hujer KM, Domitrovic TN, Bonomo RA, Russo TA, Lesczcyniecka M, Schneider T, Spellberg B.  Monoclonal Antibody Protects against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.  2017.  J Infect Dis.  216:489-501.  PMCID: PMC5853763.

175. Spellberg B.  Preserving the Health of the Public and Our Specialty.  2017.  Clin Infect Dis.  65:1597.

174. Luna BM, Ulhaq A, Yan J, Pantapalangkoor P, Nielsen T, Davies B, Actis L, Spellberg B.  Selectable markers for use in genetic manipulation of extreme drug resistant (XDR) Acinetobacter baumannii HUMC1.  2017.  mSphere.  2(2). pii: e00140-17.  PMCID: PMC5422034

173. Thompson GR III, Blair J, Wang S, Bercovitch R, Bolaris M, Van Den Akker D, Lopez R, Heidari A, Catanzaro A, Cadena J, Chin-Hong P, Spellberg B, Johnson R.  Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis.  2017.  Clin Infect Dis.  65:338-41.

172. Cheng BL, Nielsen TB, Pantapalangkoor P, Zhao F, Lee JC, Montgomery CP, Luna B, Spellberg B, Daum RS.  Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.  2017.  Human Vaccine Immunother.  13:1609-14.  PMCID: PMC5512765.

171. Spellberg B.  Sacubitril-Valsartan in Heart Failure.  2017.  Ann Int Med.  166:680.

170. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA.  Can ceftazidime/avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?  2017.  Antimicrob Agents Chemother.  61:e02243-16.

169. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B.  Clinical and Pathophysiological Overview of Acinetobacter Infections: A Century of Challenges.  2017.  Clin Microbiol Reviews.  30:409-447.  PMCID: PMC5217799

168. Spellberg B, Bartlett JB, Gilbert DN.  How to Pitch an Antibiotic Stewardship Program (ASP) to the Hospital C-Suite.  2016.  Open Forum Infect Dis.  3(4):ofw210.  PMCID: PMC5104972.

167. Spellberg B, Marr K, Brass EP.  Regulatory pathways for new antimicrobial agents: Trade-offs to keep the perfect from being the enemy of the good.  2016.  Clin Pharmacol Ther.  100:597-9.  PMCID: PMC5242400.

166. Spellberg B, Bonomo RA.  Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: “We’re Gonna Need a Bigger Boat.”  2016.  Clin Infect Dis.  63:1619-21. PMCID: PMC5146721.

165. Wei EK, Sarff L, Spellberg B.  Debunking the July Effect Myth.  2016.  J Patient Saf.  ePub.

164. Spellberg B.  The New Antibiotic Mantra: “Shorter Is Better.”  2016.  JAMA Int Med. 176:1254-5.  PMCID: PMC5233409.

163. Sartelli M…Spellberg B…Viale P (total of >100 authors).  Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).  2016.  World J Emerg Surg.  11:33-55.

162. Spellberg B, Brass EP.  The VITAL Study: Case Control Studies Are Hypothesis-Generating.  2016.  Lancet Infect Dis.  16:866.

161. Spellberg B.  Trimethoprim–Sulfamethoxazole for Uncomplicated Skin Abscess.  2016.  N Eng J Med. 375:284.

160. Wong DW, Spellberg.  Leveraging Antimicrobial Stewardship Teams to Address the Threat of Carbapenem-Resistant Enterobacteriaceae.  2016.  Virulence.  17:1-8.

159. Spellberg B, Srinivasan A, Chambers HF.  Empowering Antibiotic Stewardship Will Require New Societal Approaches.  2016.  JAMA.  315:1229-30.  PMCID: PMC5611826.

158. Rojas LJ, Taracila MA, Papp-Wallace KM, Bethel CR, Caselli E, Romagnoli C, Winkler ML, Spellberg B, Prati F, Bonomo RA.  Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design.  2016.  60:1751-9.

157. Russo TA, Spellberg B, Johnson JR.  Important Complexities of the Antivirulence Target Paradigm:  a Novel Ostensibly Resistance-Avoiding Approach for Treating Infections.  2016.  J Infect Dis.  213:901-3.  PMCID: PMC4760422.

156. Spellberg B, Brass EP.  Non-inferiority does not mean non-inferior.  2016.  Clin Infect Dis.  62:525-6.

155. Bruhn KW, Dekitani K, Nielsen T, Pantapalangkoor P, Spellberg B.  Ly6G-mediated depletion of neutrophils is dependent on macrophages.  2015.  Res Immunol.  6:5-7.  PMCID: PMC4711394.

154. Nielsen TB, Bruhn KW, Pantapalangkoor P, Junus JL, Spellberg B.  Cryopreservation of virulent Acinetobacter baumannii to reduce variability of in vivo studies.  2015.  BMC Micro Method.  15:252.  PMCID: PMC4630970.

153. Bruhn KW, Spellberg B.  Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections.  2015.  Curr Opin Microbiol.  27:57-61.  PMCID: PMC4659759

152. Spellberg B, Doi Y.  The Rise of Fluoroquinolone-Resistant E. coli in the Community: Scarier than We Thought.  2015.  J Infect Dis.  212(12):1853-5.  PMCID: PMC4620434

151. Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker DV, Detry MA, Le T, Berry SM.  A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.  2015.  J Comp Eff Res.  4:101-14.

150. Spellberg B, Bonomo R.  Combination Therapy for Extreme Drug Resistant (XDR) Acinetobacter baumannii: Ready for Prime-Time?  2015.  Crit Care Med.  43:1332-4.  PMCID: PMC4620434

149. Spellberg B, Bartlett JG, Wunderink R, Gilbert DN.  Novel Approaches Are Needed to Develop Tomorrow’s Antibacterial Therapies.  2015.  Am J Resp Crit Care Medicine.  191:135-40. PMCID: PMC4347440.

148. Fleischman RJ, Kaji AH, Diaz VM, McKenzie K, Soltero P, Van Natta TL, Spellberg B.  A Simple Intervention to Improve Hospital Flow from Emergency Department to Inpatient Units.  2015.  JAMA Internal Med.  175:289-90.

147. Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, Wright MS, Bonomo RA, Adams MD, Chen W, Spellberg B.  Host Fate Is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii Bacteremia.  2015.  J Infect Dis.  211(8):1296-305.  PMCID: PMC4447835.

146. Park H, Solis NV, Louie JS, Spellberg B, Rodriguez N, Filler SG.  Different Tumor Necrosis Factor α Antagonists Have Different Effects on Host Susceptibility to Disseminated and Oropharyngeal Candidiasis in Mice.  2014.  Virulence.  5:625-9.  PMCID: PMC4105312.

145. Chang DW, Huyhn R, Sandoval E, Han N, Coil CJ, Spellberg BJ.  Volume of Fluids Administered During Resuscitation for Severe Sepsis and Septic Shock and the Development of the Acute Respiratory Distress Syndrome.  2014.  J Crit Care.  29(6):1011-5

144. David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Seith J, Volinski J, Spellberg B.  Staphylococcus aureus Bacteremia at Five U.S. Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections.  2014.  Clin Infect Dis.  59:798-807. PMCID: PMC4200044

143. Spellberg B, Gilbert DN.  The Future of Antibiotics and Resistance: A Tribute to a Career of Leadership by John Bartlett.  2014.  Clin Infect Dis.  59(S2):S71-5.  PMCID: PMC4176319

142. Spellberg B, Shlaes D.  Prioritized Current Unmet Needs for Antibacterial Therapies.  2014.  Clin Pharm Ther.  96:151-3.

141. Kim D, Spellberg B.  Does Real-Time Feedback to Residents or Attendings Improve Medical Documentation?  2014.  J Hospital Practice.  42:123-30.

140. Spellberg B.  Community acquired pneumonia.  2014.  New Eng J Med.  370:1861-2.

139. Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG Jr. Antibacterial Resistance Leadership Group: Open for Business.  2014.  Clin Infect Dis.  58:1571-6.

138. Shimizu E, Glaspy K, Witt MD, Poon K, Black S, Schwartz S, Bholat T, Diaz N, Kuo A, Spellberg B.  Readmissions at a public safety net hospital.  2014.  PLoS One.  9:e91244. PMCID: PMC3949745.

137. Spellberg B.  The future of antibiotics.  2014.  Critical Care.  18:228-35.  PMCID: PMC4075146.

136. Lin L, Pantapalangkoor P, Tan B, Bruhn K, Ho T, Nielsen T, Skaar EP, Zhang Y, Bai R, Wang A, Doherty TM, Spellberg B.  Transferrin iron starvation therapy for lethal bacterial and fungal infections.  2014.  J Infect Diseases.  210:254-64.  PMCID: PMC4092247.

135. Luo G, Spellberg B, Gebremariam T, Lee H, Xiong YQ, French SW, Bayer A, Ibrahim AS.  Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.  2013.  Eur J Clin Microbiol Infect Dis.  33:845-51.  PMCID: PMC4090217.

134. Spellberg B.  Antibiotic Judo: Working Gently with Prescriber Psychology to Overcome Inappropriate Use.  2014.  JAMA Int Med.  174:432-3.  PMCID: PMC4064591.

133. Spellberg B, Bonomo R.  The Deadly Impact of Extreme Drug Resistance in Acinetobacter baumannii.  2014.  Critical Care Med.  42:1289-91. PMCID: PMC4184139.

132. Spellberg B, Rex J.  The Value of Single-Pathogen Antibacterial Agents.  2013.  Nature Reviews Drug Discovery.  12:963.  PMCID: PMC4012226.

131. Shlaes D, Sahm D, Opiela C, Spellberg B.  The FDA Reboot of Antibiotic Development.  2013.  Antimicrob Agents Chemother.  57:4605-7.  PMCID: PMC3811409.

130. Montgomery CP, Daniels MD, Zhao F, Spellberg B, Chong AS, Daum RS.  Local inflammation exacerbates the severity of Staphylococcus aureus skin infection.  2013.  PLoS One.  8:e69508.  PMCID: PMC3702601.

129. Thompson G, Wang S, Bercovitch R, Bolaris M, Van Den Akker D, Taylor S, Lopez R, Catanzaro A, Cadena J, Chin-Hong P, Spellberg B.  Routine CSF analysis in coccidioidomycosis is not required.  2013.  PLoS One.  8:e64249.

128. Spellberg B.  Endpoints in trials of treatment for skin infections.  2013.  JAMA.  309:2091-2.

127. Spellberg B, Bonomo RA.  “Airborne Assault:” A New Dimension in Acinetobacter baumannii Transmission.  2013.  Crit Care Medicine.  41:2042-4.  PMCID: PMC3815473.

126. Mendez CM, Harrington DW, Christenson P, Spellberg B.  Impact of Hospital Variables on Case Mix Index as a Marker of Disease Severity.  2013.  Population Health Management.  17:28-34.  PMCID: PMC3931432.

125. Bartlett JG, Gilbert D, Spellberg B.  Seven ways to preserve the miracle of antibiotics.  2013.  Clin Infect Dis.  56:1445-50.

124. Spellberg B, Taylor-Blake B.  On the Exoneration of Dr. William H. Stewart: Debunking an Urban Legend.  2013. Int J Medical Poverty.  2:3.  PMCID: PMC3707092

123. Spellberg B, Bartlett JG, Gilbert DN.  The Future of Antibiotics and Resistance.  2013.  New Eng J Med.  368:299-302.  PMCID: PMC3617123

122. Russo T, Beanan J, Olson R, MacDonald U, Cox A, St. Michael F, Vinogradov E, Spellberg B, Luke-Marshall N, Campagnari A.  The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.  2013.  Infect Immun.  81:915-22. PMCID: PMC3584894

121. Spellberg B, Harrington D, Black S, Sue D, Stringer W, Witt M.  Capturing the diagnosis:  an internal medicine education program to improve documentation.  2013.  Am J Med.  126:739-43.

120. Lin L, Tan B, Pantapalangkoor P, Ho T, Hujer AM, Taracila MA, Bonomo RA, Spellberg B.  Acinetobacter baumannii rOmpA Vaccine Dose Alters Immune Polarization and Immunodominant Epitopes.  2013.  Vaccine.  31:313-8.  PMCID: PMC3557524.

119. Spellberg B, Sue D, Chang D, Witt M.  Change in Cross-Cover Calls at Night after a Work Hour Restriction Process Change.  2013.  JAMA Int Med.  173:707-9.

118. Spellberg B, Brass EP, Bradley JS, Lewis R, Shlaes D, Ambrose P, Das A, Boucher HW, Doi Y, Bartlett JG, Bonomo RA, Larosa SP, Talbot GH, Benjamin D, Guidos RJ, Jezek A, Gilbert DN, on behalf of the Infectious Diseases Society of America.  White Paper:  Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens.  2012.  Clin Infect Dis.  55:1031-46. PMCID: PMC3657525

117. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock REW, Adams MD, French SW, Buslon VS, Spellberg B.  LpxC Inhibition Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis.  2012.  mBio.  3: e00312-12.  PMCID: PMC3518917

116. Shlaes DM, Spellberg B.  Overcoming the challenges to developing new antibiotics.  2012.  Current Opinions in Pharmacology.  12:522-6.

115. Spellberg B, Lewis RJ, Sue D, Chavoshan B, Vintch J, Munekata M, Kim C, Lanks C, Witt MD, Stringer W, Harrington D.  A controlled investigation of optimal internal medicine ward team structure at a teaching hospital.  2012.  PLoS One.  7: e35576  PMCID: PMC3330818

114. Spellberg B.  Gastrointestinal mucormycosis: an evolving disease.  2012.  Gastroenterology and Hepatology.  8:140-142.

113. Spellberg B, Kontoyiannis D, Fredricks D, Morris M, Perfect J, Chin-Hong PV, Ibrahim AS, Brass EP.  Risk factors for mortality in patients with mucormycosis.  Medical Mycol. 2012. 50:611-8.

112. Luo G, Spellberg B, Gebremariam T, Bolaris M, Lee H, Fu Y, French SW, Ibrahim AS.  Diabetic Murine Models for Acinetobacter baumannii Infection.  J Antimicrob Chemotherapy.  2012.  67:1439-45.

111. Kontoyiannis DP, Lewis RE, Lortholary O, Spellberg B, Petrikkos G, Roillides E, Ibrahim AS, Walsh TJ.  Future Directions in Mucormycosis Research.  Clin Infect Dis.  2012.  54(S1):S79-S85.

110. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ.  How Does Antifungal Pharmacology Differ for Mucormycosis vs. Aspergillosis?  Clin Infect Dis.  2012.  I54(S1):S67-S72.

109. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP.  Pathogenesis of mucormycosis.  Clin Infect Dis.  2012.  54(S1):16-S22.

108. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lothorlary O, Petrikkos G, Kontoyiannis DP, Walsh TJ.  Combination Therapy for Mucormycosis: Why, What, and How?  Clin Infect Dis.  2012.  54(S1):S73-S78

107. Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B.  Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection.  PLoS One.  2012.  7(1): e29446.  PMCID: PMC3254619

106. Spellberg B, Sharma P, Rex J.  The Critical Impact of Time Discounting on Economic Incentives to Overcome the Antibiotic Market Failure.  Nat Rev Drug Discovery.  2012. 11:168.

105. Spellberg B, Daum RS.  Development of a vaccine against Staphylococcus aureus.  Seminars Immunopathol.  2011.  34:335-48. 

104. Daum RS, Spellberg B.  Progress toward a Staphylococcus aureus vaccine.  Clin Infect Dis.  2012.  54:560-7.  PMCID: PMC3404717

103. Spellberg B, Lipsky BA.  Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults.  Clin Infect Dis.  2012.  54:393-407.  PMCID: PMC3491855

102. Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B.  Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic, oritavancin.  Clin Infect Dis.  2012.  54(S3):S229-32. PMCID: PMC3307583

101. Adams-Haduch JM, Onuoha EO, Bogdanovich T, Tian GB, Marschall J, Urban CM, Spellberg BJ, Rhee D, Halstead DC, Pasculle AW, Doi Y.  Molecular Epidemiology of Carbapenem-Non-Susceptible Acinetobacter baumannii in the United States.  J Clin Microbiol.  2011.  49:3849-54.

100. Lin L, Ibrahim AS, Baquir B, Palosaari A, Spellberg B.  Luminescent Activated Transfected Killer (ATAK) Cells to Monitor Leukocyte Trafficking During Systemic Bacterial and Fungal Infection.  2012.  J Infect Dis.  205:337-47.  PMCID: PMC3244365

99. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris M, Perfect JR, Fredricks D, Brass EP.  The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study: A Randomized, Double-Blinded Placebo Controlled Trial.  J Antimicrob Chemother.  2012.  67:715-22.  PMCID: PMC3383100

98. Spellberg B.  Acute Bacterial Skin and Skin Structure trials: The Bad is the Enemy of the Good.  Clin Infect Dis.  2011.  53:1308-9.

97. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN.  IDSA Policy Paper: Combating Antimicrobial Resistance.  Clin Infect Dis.  2011.  52(S5):S397-S428.  PMCID: PMC3738230

96. Ibrahim AS, Gebremariam T, Luo G, Fu Y, French SW, Edwards J, Spellberg B.  Combination Therapy of Murine Mucormycosis or Aspergillosis with Iron Chelation, Polyenes and Echinocandins.  Antimicrob Agents Chemother.  2011.  55:1768-70.

95. Spellberg B.  Vaccines for invasive fungal infections.  F1000 Med Rep.  2011.  3:13.  PMCID: PMC3155210.

94. Spellberg B.  The Antibiotic Crisis: Can We Reverse 65 Years of Failed Stewardship?  Arch Int Med.  2011.  171:1080-1.  PMCID: PMC3197824

93. Miller LG, McKinnel J, Vollmer M, Spellberg B.  The Impact of Methicillin-Resistant Staphylococcus aureus Prevalence on Surgical Site Infection Risk After Coronary Artery Bypass Surgery. Infect Control Hospital Epidemiol.  2011.  32:342-50. PMCID: PMC3193178

92. Spellberg B, Lewis RJ, Boucher HW, Brass EP.  Design of Clinical Trials of Antibacterial Agents for Community Acquired Bacterial Pneumonia.  Clin Invest.  2011.  1:19-32.  PMCID: PMC3173946.

91. Geraci T, Spellberg B.  Pulmonary tuberculosis at an urban hospital in the US: a five year experience.  Infect Dis Clin Practice.  2011.  19:182-186.**

90. Gilbert DN, Spellberg B, Bartlett JG, for the Infectious Diseases Society of America.  Position Paper. An unmet medical need: rapid molecular diagnostic tests for respiratory tract infections.  Clin Infect Dis. 2011.  52(S4):S384-S395. (**indexed in PubMed with IDSA as the author line)

89. Spellberg B.  Clarifying Bandemia: How Accurate Are Automated Laboratory Flags?  Infect Dis Clin Practice.  2011.  18:353-354.**

88. Spellberg B, Daum RS.  A new view on development of a Staphylococcus aureus vaccine: insights from mice and men.  Human Vaccines.  2011.  6:857-9.  PMCID: PMC3049966

87. Spellberg B, Boucher H, Bradley J, Das A, Talbot G.  To Treat or Not To Treat: Adjunctive Antibiotics for Uncomplicated Abscesses.  Ann Emergency Med.  2011.  57(2):183-5.  PMCID: PMC3074575

86. Spellberg B, Ibrahim AS.  Recent Advances in the Treatment of Mucormycosis.  Curr Infect Dis Reports.  2010.  12:423-9.

85. Spellberg B.  Skin and soft tissue infections: modern evolution of an ancient problem.  Clin Infect Dis.  2010.  51:904-906.  PMCID: PMC2944015

84. Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, Fu Y, French SW, Edwards JE Jr., Spellberg B.  The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis.  Molecular Microbiol.  2010. 77:587-604.

83. Spellberg B.  Geographic differences in Medicare spending.  New Eng J Med.  2010.  363:1677-78.

82. Gilbert DN, Guidos RJ, Boucher HW, Talbot GH, Spellberg B, Edwards JE, Scheld WM, Bradley JS, Bartlett JG, for the Infectious Diseases Society of America.  The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020. Clin Infect Dis. 2010. 50:1081-3.

81. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, Edwards J, Filler SG, Ibrahim AS.  Endothelial cell GRP78 is a novel receptor required for mucormycosis pathogenesis in diabetic mice.  J Clin Invest. 2010. 120:1914-24.

80. Quan C, Spellberg B.  Mucormycosis, Pseudallescheriasis, and other uncommon mold infections.  Proc Am Thoracic Society.  2010.  7:210-15.

79. Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, Fu Y.  Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target.  J Infect Dis. 2010. 201:1718-28.  PMCID: PMC3933264.

78. Lin L, Ibrahim AS, Baquir B, Fu Y, Applebaum D, Schwartz J, Wang A, Avanesian V, Spellberg B.  Safety and Efficacy of Activated Transfected Killer (ATAK) Cells for Neutropenic Fungal Infections.  J Infect Dis. 2010.  201:1708-17.  PMCID: PMC2873231

77. Spellberg B, Talbot GH.  Position Paper: Recommended Design Features of Future Clinical Trials of Anti-Bacterial Agents for Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP).  For the Infectious Diseases Society of America (IDSA), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), and Society of Critical Care Medicine (SCCM).  Clin Infect Dis. 2010.  51(S1):S150-S170.  PMCID: PMC294785

76. Baquir B, Lin L, Ibrahim AS, Fu Y, Avanesian V, Tu A, Edwards J Jr, Spellberg B.  Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein.  J Infect Dis. 2010.  201:473-7.  PMCID: PMC2812804

75. Ibrahim A, Gebremariam T, French S, Edwards J, Spellberg B. The Iron Chelator Deferasirox Enhances Liposomal Amphotericin B Efficacy in Treating Murine Invasive Pulmonary Aspergillosis.  J Antimicrobial Chemother.  2010.  65:289-92.

74. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE Jr., Spellberg B.  Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.  PLoS Pathogens.  2009.  5: e1000703.  PMCID: PMC2792038

73. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS.  Recent advances in the management of mucormycosis: from bench to bedside.  Clin Infect Dis.  2009.  48:1743-51.

72. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, Walsh TJ, Ibrahim AS.  Safety and Outcomes of Open Label Deferasirox Iron Chelation Therapy for Mucormycosis.  Antimicrob Agents Chemother.  2009. 53:3122-5.  PMCID: PMC2704638

71. Spellberg B, Talbot GH, Boucher HW, Bradley JS, Gilbert D, Scheld WM, Edwards JE Jr., Bartlett JG.  Antimicrobial agents for complicated skin and skin structure infections: justification of non-inferiority margins in the absence of placebo-controlled trials.  For the Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA).  Clin Infect Dis.  2009.  49(3):383-91.  PMCID: PMC2808402

70. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE Jr, Spellberg B.  Posaconazole mono- or combination therapy for treatment of murine zygomycosis.  Antimocrob Agents Chemother.  2009.  53:772-5.  PMCID: PMC2630615

69. Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B, Arnold S, Lentnek A, Wheat LJ.  Voriconazole Use for Endemic Fungal Infections.  Antimicrob Agents Chemother.  2009.  53(4):1648-51.

68. Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B.  Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus.  FEMS Immunol Med Microbiol.  2009.  55:293-5.  PMCID: PMC2801022

67. Ibrahim AS, Spellberg B, Edwards JE Jr.  Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.  Curr Opin Infect Dis.  2008.  21:620-5.

66. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J.  Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America.  Clin Infect Dis. 2008  48(1):1-12.

65. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, Bayer AS, Filler SG, Lipke P, Otoo H, Edwards JE Jr.  The anti-fungal rAls3p-N vaccine protects mice against the bacterium Staphylococcus aureus.  Infect Immun.  2008.  76:4574-80.  PMCID: PMC2546811

64. Ibrahim AS, Bryant R, Edwards JE JR., Spellberg B.  Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?  Med Mycol. 2008.  16:1-9.  PMCID: PMC2793326

63. Spellberg B.  Dr. William H. Stewart: Mistaken or Maligned?  Clin Infect Dis.  2008.  47:294.

62. Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert D.  Position Paper: Recommended Design Features of Future Clinical Trials of Anti-Bacterial Agents for Community-Acquired Pneumonia.  Infectious Diseases Society of America.  Clin Infect Dis.  2008.  47:S249-65.

61. Spellberg B, Fleming TR, Gilbert D.  Executive Summary.  Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community-Acquired Pneumonia.  Co-sponsored by the FDA and IDSA.  Clin Infect Dis.  2008.  47:S105-7.

60. Spellberg B, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards Jr JE.  Reply to Kunin: Rationale for Antibiotic Development Incentives.  Clin Infect Dis.  2008.  46:1792-93.

59. Ibrahim AS, Gebremariam T, Liu M, Chamilos G, Kontoyiannis DP, Mink R, Kwon-Chung KJ, Fu Y, Skory CD, Edwards JE Jr., Spellberg B.  Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to mucormycosis pathogenesis.  J Infect Dis.  2008.  198:1083-90.  PMCID: PMC2546811

58. Spellberg B.  Antibiotic resistance and antibiotic development.  Lancet Infect Dis.  2008.  8:211-12.

57. Spellberg B.  Vaccine prospects for invasive fungal infections.  J Invasive Fungal Infect.  2008. 2:18-24.**

56. Ibrahim AS, Gebremariam T, Husseiny M, Stevens D, Fu Y, Edwards JE Jr, Spellberg B.  Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis.  Antimicrob Agents Chemother.  2008.  52:1573-6.  PMCID: PMC2292510

55. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B.  Combination Echinocandin-Polyene Treatment of Murine Mucormycosis.  Antimicrob Agents Chemother.  2008.  52:1556-8.  PMCID: PMC2292548

54. Fu Y, Luo G, Spellberg BJ, Edwards JE Jr, Ibrahim AS.  Gene Overexpression/Suppression Analysis of Candidate Virulence Factors of Candida albicans.  Eukaryot Cell.  2008.  7:483-94.

53. Spellberg B.  Novel Insights Into Disseminated Candidiasis: Pathogenesis Research and Clinical Experience Converge.  PLoS Pathogen. 2008.  4:e38.  PMCID: PMC2242839

52. Reed C, Bryant R, Ibrahim AS, Edwards JE Jr., Filler SG, Goldberg R, Spellberg B.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.  Clin Infect Dis. 2008. 47:364-71.  PMCID: PMC2793535

51. Lin L, Ibrahim AS, Avanesian V, Edwards JE Jr., Fu Y, Baquir B, Taub R, Spellberg B.  Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.  Clin Vaccine Immunol.  2008.  15:582-4.  PMCID: PMC2268268

50. Spellberg B, Ibrahim AS, Lin L, Avanesian V, Fu Y, Lipke P, Otoo H, Ho T, Edwards JE Jr.  An antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity.  J Infect Dis. 2008.  197:957-71.  PMCID: PMC2242839

49. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards JE Jr, for the Infectious Diseases Society of America (IDSA).  The Epidemic of Antibiotic Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America.  Clin Infect Dis.  2008.  46:155-64.

48. Spellberg B.  Prospects for and barriers to a fungal vaccine.  Exp Opinion Biological Ther.  2007.  7:1785-8.

47. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny M, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation.  J Clin Invest.  2007.  117:2649-2657.  PMCID: PMC1957543

46. Perlroth J, Choi B, Spellberg B.  Nosocomial Fungal Infections: Epidemiology, Diagnosis, and Treatment.  Medical Mycol  2007.  45:321-46.

45. Spellberg B, Miller LG, Kuo MD, Bradley J, Scheld WM, Edwards JE Jr.  Societal Costs Versus Savings from Wild-Card Patent Extension Legislation to Spur Critically Needed Antibiotic Development Infection.  Infection  2007.  35:1-8.

44. Spellberg B, Collins M, Avanesian V, Gomez M, Edwards JE Jr., Cogle C, Applebaum C, Fu Y, Ibrahim AS.  Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.  J Leuk Biol 2007. 81:632-41.

43. Miller LG, Perdreau-Remington F, Bayer AS, Diep B, Tan N, Tsui J, Bharadwa K, Perlroth J, Shay A, Tagudar G, Ibebuogu U, Spellberg B. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant from methicillin-susceptible Staphylococcus aureus infection: a prospective investigation. Clin Infect Dis  2007.  44:471-82.

42. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B.  Deferasirox, an Iron-chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis.  Antimicrob Agents Chemother 2006.  50:3968-9.

41. Spellberg B, Schwartz J, Fu Y, Avanesian V, Adler-Moore J, Edwards JE Jr., Ibrahim A.  Comparison of antifungal treatments for murine fusariosis.  J Antimicrob Chemother. 2006.  58:973-9.

40. Ibrahim AS, Edwards JE Jr., Fu Y, Spellberg B.  Deferiprone iron chelation as a novel therapy for experimental mucormycosis.  J Antimicrob Chemother.  2006.  58:1070-3.

39. Rieg G, Spellberg B, Schwartz J, Fu Y, Edwards JE Jr., Sheppard DC, Ibrahim AS.  Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.  Antimicrob Agents Chemother.  2006.  50:2895-6.

38. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, Filler SG, Yeaman MR, Edwards JE Jr.  Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.  J Infect Dis.  2006.  194:256-60.

37. Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y, Edwards JE Jr.  The anti-Candida rAls1p-N vaccine is broadly active against disseminated candidiasis.  Infect Immun.  2006.  74:3039-41.

36. Spellberg B.  IgG2 antibodies and HIV Long Term Non-progressors: What is the Mechanism?  J Infect Dis.  2006.  193:1047.

35. Spellberg B, Filler SG, Edwards JE Jr.  Current treatment strategies for disseminated candidiasis.  Clin Infect Dis.  2006.  42:244-51.

34. Spellberg B, Ibrahim A.  Gastric mucormycosis: a nosocomial problem.  Gastroenterol & Hepatol.  2005.  1:129-130. **

33. Spellberg BJ, Ibrahim AS, Avenissian V, Filler SG, Myers CL, Fu Y, Edwards JE Jr.  The anti-Candida albicans rAls1p-N vaccine reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.  Infect Immun. 2005.  73:6191-6193.


32. Spellberg B, Collins M, French SW, Edwards JE Jr., Fu Y, Ibrahim AS.  A phagocytic cell-line markedly improves survival of infected neutropenic mice.  J Leuk Bio. 2005.  78:338-44

31. Spellberg B, Edwards JE Jr., Ibrahim AS.  2005.  Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management.  Clin Microbiol Rev.  18:556-69.

30. Spellberg B, Ibrahim AS, Edwards JE Jr., Filler SG.  Mice with disseminated candidiasis die of progressive sepsis.  2005.  J Infect Dis.  192:336-43.

29. Miller LG, Pedreau-Remington F, Rieg G , Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. 2005.  New Eng J Med. 352:1445-53.

28. Spellberg B. Clausewitz and cholera: the cause of World War II?  2005.  J Med Biography.  13:108-112.

27. Spellberg B.  Is computed tomography of the head useful before lumbar puncture?  2005.  Clin Infect Dis.  2005.  40:1061.

26. Spellberg B, Fu Y, Edwards JE Jr., Ibrahim AS.  Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.  2005.  Antimicrob Agents Chemother. 49:830-32.

25. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE Jr., Douglas CM.  Caspofungin inhibits Rhizopus oryzae 1,3-b-D glucan synthase, lowers qPCR-measured brain burden, and improves survival at a low but not a high dose during murine disseminated zygomycosis.  2005.  Antimicrob Agents Chemother.  49:721-27.

24. Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG, Edwards JE Jr.  Vaccination with rAls1p-N improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.  2005.  Infect Immun.  73:999-1005.

23. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr.  Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro.  2005.  Infect Immun.  73:778-83.

22. Miller LG, Spellberg B. Spider Bites and Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus aureus. 2004.  Surgical Infect. 5: 321-2.

21. Spellberg B, Yoo T, Bayer AS.  Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6.  2004.  J Antimicrob Chemother.  54:832-5.

20. Miller LG, Spellberg B.  Treatment of Community-Associated Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections With Drainage But No Antibiotic Therapy.  2004.  Pediatr Infect Dis J.  23:795.

19. Fu Y, Lee H, Collins M, Tsai H, Spellberg B, Edwards JE Jr., Kwon-Chung KJ, Ibrahim AS.  Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene.  2004.  FEMS Microbiology Letters.  235:169-176.

18. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future.  2004.  Clin Infect Dis. 38(9):1279-86.

17. Spellberg B, Witt MD, Beck CK. 2004. Amphotericin B: is a lipid-formulation “gold-standard” feasible?  Clin Infect Dis. 38:304-5.

16. Ibrahim AS, Avanesian V, Spellberg B, Edwards JE Jr.  2003.  Liposomal Amphotericin B, and not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae.  Antimicrob Agents Chemother.  47:3343-3344.

15. Spellberg B, Johnston D, Phan QT, Edwards JE Jr, French SW, Ibrahim AS, Filler SG.  2003.  Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.  Infect Immunity.  71:5756-5764.

14. Spellberg B, Rieg G, Bayer AS, Edwards JE Jr.  2003.  Lack of cross-hepatotoxicity between fluconazole and voriconazole.  Clin Infect Dis.  36:1091-3.

13. Spellberg B, Edwards JE Jr.  2002.  The pathophysiology and treatment of Candida sepsis.  Curr Infect Dis Reports.  4:387-99.

12. Spellberg B, Carroll RM, Robinson E, Brass E.  2001.  mtDNA disease in the primary care setting.  Arch Intern Med.  161:2497-2500.

11. Spellberg B, Edwards JE Jr.  2001.  Type 1/Type 2 immunity in infectious diseases.  Clin Infect Dis.  32:76-102.

10. Spellberg B.  The cutaneous citadel : A holistic view of skin and immunity.  2000.  Life Sciences.  67(5):477-502.

9. Spellberg B, Schiller GS.  1999.  Autologous bone marrow transplantation for acute leukemia.  Hematology-Oncology Clin N Amer.  13(5):919-938.

8. Spellberg B.  Mechanism of Intravenous Immune Globulin Therapy.  1999.  New Eng J Med.  341(1):57-8.

7. Wirshing DA, Spellberg B, Erhart SM, Marder SR, Wirshing WC.  1998.  Novel antipsychotics and new-onset diabetes.  Biological Psychiatry.  44:778-83.

6. Deirmenjian JM, Erhart SM, Wirshing DA, Spellberg BJ, Wirshing WC. 1998.  Olanzapine-induced reversible priapism: a case report.  J Clin Psychopharmacol.  18(4):1-2.

5. Fu Y, Filler SG, Spellberg B, Fonzi W, Ibrahim AS, Kanbe T, Ghannoum MA, Edwards JE Jr.  1998.  Cloning and characterization of CAD/AAF1, a gene from Candida albicans that induces adherence to endothelial cells after expression in Saccharomyces cerevisiae.  Infection Immun.  66(5):2078-84.

4. Libraty DH, Airan LE, Uyemura K, Jullien D, Spellberg B, Rea TH, Modlin RL.  1997.  Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.  J Clin Invest.  99(2):336-41

3. Filler SG, Pfunder AS, Spellberg BJ, Spellberg JP, Edwards JE Jr.  1996.  Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells.  Infection Immun.  64(7):2609-17.

2. Ghannoum MA, Spellberg B, Saporito-Irwin SM, Fonzi WA.  1995.  Reduced virulence of Candida albicans PHR1 mutants.  Infection Immun.  63(11):4528-30.

1. Ghannoum MA, Spellberg BJ, Ibrahim AS, Ritchie JA, Currie B, Spitzer ED, Edwards JE Jr., Casadevall Al.  1994.  Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole.  Antimicrobial Agents Chemother.  38(9):2029-33.